Saxagliptin (Onglyza®): New inhibitor of the dipeptidylpeptidase-4 for the oral treatment of type 2 diabetes;Saxagliptine (Onglyza®): Nouvel inhibiteur de la dipeptidylpeptidase-4 pour le traitement oral du diabète de type 2

Revue Medicale de Liege

Volumn 65, Issue 9, 2010, Pages 527-532

  Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Glucagon like peptide 1; Incretin; Saxagliptin; Type 2 diabetes

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG DERIVATIVE;

ARTICLE; DIET THERAPY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; WEIGHT GAIN; CLINICAL TRIAL (TOPIC);

ADAMANTANE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS;

EID: 77958038724     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Diab DL, D'Alessio DA. - The contribution of enteroinsular hormones to the pathogenesis of type 2 diabetes mellitus. Curr Diab Rep, 2010, 10, 192-198.
2. Scheen AJ. - Le glucagon-like peptide-1 (GLP-1), nouvelle cible dans le traitement du diabète de type 2. Rev Med Liège, 2007, 62, 216-219.
3. Scheen AJ, Radermecker RP, Philips JC, Paquot N. - Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse, 2007, 3, 1884-1888. (Pubitemid 47425207)
4. Neumiller JJ, Wood L, Campbell RK. - Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30, 463-484.
5. Scheen AJ, Van Gaal LF. - Sitagliptine (Januvia®). Incrétinopotentiateur indiqué comme insulinosécré tagogue dans le traitement du diabète de type 2. Rev Med Liège, 2008, 63, 105-109.
6. Scheen AJ, Paquot N. - Vildagliptine (Galvus®) et combinaison fixe vildagliptine-metformine (Eucreas®), dans le traitement du diabète de type 2. Rev Med Liège, 2009, 64, 161-167.
7. Scheen AJ, Radermecker RP. - Addition of incretin therapy to metformin in type 2 diabetes. Lancet, 2010, 375, 1410-1412.
8. Scheen AJ. - Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Exp Opin Drug Metab Toxicol, 2010, Aug 13 [Epub ahead of print].
9. Scheen AJ, Van Gaal LF. - Exénatide (Byetta®). Incrétinomimétique indiqué dans le traitement du diabète de type 2 après échec et en complément des antidiabétiques oraux. Rev Med Liège, 2008, 63, 158-165.
10. Scheen AJ, Van Gaal LF. - Liraglutide (Victoza®). Analogue du glucagon-like peptide-1 humain en une injection par jour pour le traitement du diabète de type 2. Rev Med Liège, 2010, 65, 464-470.
11. Dhillon S, Weber J. - Saxagliptin. Drugs, 2009, 69, 2103-2114.
12. Borja-Hart NL, Whalen KL. - Saxagliptin : a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes. Ann Pharmacother, 2010, 44, 1046-1053.
13. Scheen AJ. - Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab, 2010, 12, 648-658.
14. Scheen AJ. - Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions. Clin Pharmacokinet, 2010, 49, 573-588.
15. Rosenstock J, Sankoh S, List JF. - Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab, 2008, 10, 376-386.
16. Rosenstock J, Aguilar-Salinas C, Klein E, et al. - Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin, 2009, 25, 2401-2411.
17. DeFronzo RA, Hissa M, Garber AJ, et al. - The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care, 2009, 32, 1649-1655.
18. Chacra AR, Tan GH, Apanovitch A, et al. - Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes : a randomised controlled trial. Int J Clin Pract, 2009, 63, 1395-1406.
19. Hollander P, Li J, Allen E, Chen R, for the CV181-013 investigators. - Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab, 2009, 94, 4810-4819.
20. Jadzinsky M, Pfützner A, Paz-Pacheco E, et al. - Saxagliptin given in combination with metformin as initial therapy improves glycemic control in patients with type 2 diabetes compared with either monotherapy : a randomized controlled trial. Diabetes Obes Metab, 2009, 11, 611-622.
21. Scheen AJ, Charpentier G, Östgren CJ, et al. - Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev, 2010, in press (DOI : 10.1002/dmrr.1114).
22. Fakhoury WK, Lereun C, Wright D. - A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology, 2010, 86, 44-57.
23. Frederich R, Alexander JH, Fiedorek FT, et al. - A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med, 2010, 122, 16-27.